Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview

Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in palliative setting and last but not least, systemic treatment. The la...

Full description

Bibliographic Details
Main Authors: Diederick J. van Doorn, Robert Bart Takkenberg, Heinz-Josef Klümpen
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Pharmaceuticals
Subjects:
hepatocellular carcinoma (HCC), immunotherapy
systemic therapy
checkpoint inhibition
outcome
toxicity
tolerability
Online Access:https://www.mdpi.com/1424-8247/14/1/3

Internet

https://www.mdpi.com/1424-8247/14/1/3

Similar Items